Chymase inhibitor prevents the nonalcoholic steatohepatitis in hamsters fed a methionine- and choline-deficient diet

Hepatology Research

Volumn 40, Issue 5, 2010, Pages 514-523

  Tashiro, Keitaro ^a,b   Takai, Shinji ^a   Jin, Denan ^a   Yamamoto, Hiromi ^b   Komeda, Koji ^b   Hayashi, Michihiro ^b   Tanaka, Kazuhiko ^b   Tanigawa, Nobuhiko ^b   Miyazaki, Mizuo ^a  

^a Department of Pharmacology ^*  (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin II; Chymase; Fibrosis; Nonalcoholic steatohepatitis; Steatosis

Indexed keywords

2 [4 (5 FLUORO 3 METHYLBENZO[B]THIOPHEN 2 YL)SULFONAMIDO 3 METHANESULFONYLPHENYL]THIAZOLE 4 CARBOXYLIC ACID; ANGIOTENSIN II; BILIRUBIN; CHOLINE; CHYMASE INHIBITOR; GELATINASE B; HYALURONIC ACID; MALONALDEHYDE; METHIONINE; PLACEBO; TRIACYLGLYCEROL; TY 51469; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HAMSTER; HISTOPATHOLOGY; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER WEIGHT; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77954373221     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00627.x     Document Type: Article

References (44)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-31.
2. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002, 122:1649-57.
3. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Ciln Proc 1980, 55:434-8.
4. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990, 11:74-80.
5. Bugianesi E, Leone N, Vanni E. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-40.
6. Day CP, James OF. Steatohepatitis: a tale of two " hits" Gastroenterology 1998, 114:842-5.
7. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002, 16:663-78.
8. Ramesh S, Sanyal AJ. Evaluation and management of non-alcoholic steatohepatitis. J Hepatol 2005, 42(1):S2-12. Suppl
9. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003, 38:413-19.
10. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-?1 level and efficacy of ?-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001, 15:1667-72.
11. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 2003, 38:1008-17.
12. Farrell DJ, Hines JE, Walls AF, Kelly PJ, Bennett MK, Burt AD. Intrahepatic mast cells in chronic liver disease. Hepatology 1995, 22:1175-81.
13. Armbrust T, Batusic D, Ringe B, Ramadori G. Mast cells distribution in human liver disease and experimental rat liver fibrosis. Indications for mast cell participation in development of liver fibrosis. J Hepatol 1997, 26:1042-54.
14. Matsunaga Y, Kawasaki H, Terada T. Stromal mast cells and nerve fibers in various chronic liver diseases: relevance to hepatic fibrosis. Am J Gastroenterol 1999, 94:1923-32.
15. Uno M, Kurita S, Misu H. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis. Hepatology 2008, 48:109-18.
16. Palaniyandi SS, Nagai Y, Watanabe K. Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats. Exp Biol Med 2007, 232:1213-21.
17. Chen LY, Li P, He Q, Jiang LQ, Cui CJ, Xu L, Liu LS. Transgenic study of the function of chymase in heart remodeling. J Hypertens 2002, 20:2047-55.
18. Shimizu S, Satomura K, Aramaki T, Katsuta Y, Takano T, Omoto Y. Hepatic chymase level in chronic hepatitis: co-localization of chymase with fibrosis. Hepatol Res 2003, 27:62-6.
19. Ikura Y, Ohsawa M, Shirai N. Expression of angiotensin II type 1 receptor in human cirrhotic livers: Its relation to fibrosis and portal hypertension. Hepatol Res 2005, 32:107-16.
20. Komeda K, Jin D, Takai S. Significance of chymase-dependent angiotensin II formation in the progression of human liver fibrosis. Hepatol Res 2008, 38:501-10.
21. Takai S, Shiota N, Yamamoto D, Okunishi H, Miyazaki M. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci 1996, 58:591-7.
22. Inoue N, Muramatsu M, Jin D. Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. Atherosclerosis 2009, 204:359-64.
23. Yamashita C, Hayashi T, Mori T. Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice. Hypertens Res 2007, 30:1219-30.
24. Jin D, Takai S, Yamada M, Sakaguchi M, Yao Y, Miyazaki M. Possible roles of cardiac chymase after myocardial infarction in hamster hearts. Jpn J Pharmacol 2001, 86:203-14.
25. Shiota N, Okunishi H, Takai S. Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. Circulation 1999, 99:1084-90.
26. Yokohama S, Yoneda M, Haneda M. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222-5.
27. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-? expression in rat glomerular mesangial cells. J Clin Invest 1994, 93:2431-7.
28. Bataller R, Ginès P, Nicolás JM. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000, 118:1149-56.
29. Hirose A, Ono M, Saibara T. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007, 45:1375-81.
30. Iwata K, Sohda T, Irie M. Angiotensin II type 1 receptor antagonist improves the prognosis in rats displaying liver cirrhosis induced by a choline-deficient diet. J Gastrointestin Liver Dis 2008, 17:21-5.
31. Takai S, Jin D, Sakaguchi M. A novel chymase inhibitor, 4-[1-([bis-(4-methyl- phenyl)-methyl]-carbamoyl)3-(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther 2003, 305:17-23.
32. Jin D, Ueda H, Takai S. Effect of chymase inhibition on the arteriovenous fistula stenosis in dogs. J Am Soc Nephrol 2005, 16:1024-34.
33. Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Chayama K. Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol 2009, 50:1226-35.
34. Ljumovic D, Diamantis I, Alegakis AK, Kouroumalis EA. Differential expression of matrix metalloproteinases in viral and non-viral chronic liver diseases. Clin Chim Acta 2004, 349:203-11.
35. Fang KC, Raymond WW, Blount JL, Caughey GH. Dog mast cell alpha-chymase activates progelatinase B by cleaving the Phe88-Gln89 and Phe91-Glu92 bonds of the catalytic domain. J Biol Chem 1997, 272:25628-35.
36. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005, 280:9291-6.
37. Furubayashi K, Takai S, Jin D. Chymase activates promatrix metalloproteinase-9 in human abdominal aortic aneurysm. Clin Chim Acta 2008, 388:214-16.
38. Furubayashi K, Takai S, Jin D. The significance of chymase in the progression of abdominal aortic aneurysms in dogs. Hypertens Res 2007, 30:349-57.
39. Longley BJ, Tyrrell L, Ma Y. Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc Natl Acad Sci USA 1997, 94:9017-21.
40. Tsunemi K, Takai S, Nishimoto M. A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[3,4-dioxo-1- phenyl-7-(2-pyridyloxy)]-2-heptyl] acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters. J Pharmacol Exp Ther 2004, 309:879-83.
41. Maruichi M, Takai S, Sugiyama T. Role of chymase on growth of cultured canine Tenon's capsule fibroblasts and scarring in a canine conjunctival flap model. Exp Eye Res 2004, 79:111-18.
42. He S, Walls AF. Human mast cell chymase induces the accumulation of neutrophils, eosinophils and other inflammatory cells in vivo. Br J Pharmacol 1998, 125:1491-500.
43. Terakawa M, Tomimori Y, Goto M, Fukuda Y. Mast cell chymase induces expression of chemokines for neutrophils in eosinophilic EoL-1 cells and mouse peritonitis eosinophils. Eur J Pharmacol 2006, 538:175-81.
44. Ishida K, Takai S, Murano M. Role of chymase-dependent matrix metalloproteinase-9 activation in mice with dextran sodium sulfate-induced colitis. J Pharmacol Exp Ther 2008, 324:422-6.